案例报告:格菲提尼布在EGFR 19del复发性侵袭性纤维素瘤中
Yanjing Guo1,2, Jingjing Wu3, Qianming Bai2,4
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Frontiers in oncology
|July 29, 2025
概括
这项研究报告了一例罕见的侵袭性纤维化和家族性腺瘤多重症病例,该病例发生在患有表皮生长因子受体 (EGFR) 19del突变的男性患者身上. 作为EGFR-氨酸激酶抑制剂的盖菲提尼布显示出显著的反应,主要的副作用是2级皮疹.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 胃肠病学 胃肠病学
背景情况:
- 侵袭性纤维素瘤和家族性腺瘤多重症是罕见的疾病.
- 表皮生长因子受体 (EGFR) 突变在各种癌症中很常见.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
10.3K
